Jacobs G, Emblin K, Kadam U, Daniels R, Alallan M, Mokbel K
In Vivo. 2024; 39(1):548-558.
PMID: 39740893
PMC: 11705105.
DOI: 10.21873/invivo.13859.
Sun Q, Karwi Q, Wong N, Lopaschuk G
Cardiovasc Res. 2024; 120(16):1996-2016.
PMID: 39453987
PMC: 11646102.
DOI: 10.1093/cvr/cvae231.
Lopaschuk G, Dyck J
Nat Cardiovasc Res. 2024; 2(5):425-437.
PMID: 39196044
DOI: 10.1038/s44161-023-00259-1.
Giardinelli S, Meliota G, Mentino D, DAmato G, Faienza M
Int J Mol Sci. 2024; 25(15).
PMID: 39125850
PMC: 11313011.
DOI: 10.3390/ijms25158280.
Shah A, Sabharwal N, Day J
BJA Educ. 2024; 24(5):155-163.
PMID: 38646450
PMC: 11026937.
DOI: 10.1016/j.bjae.2024.02.003.
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors.
Verma S, Mudaliar S, Greasley P
Adv Ther. 2023; 41(1):92-112.
PMID: 37943443
PMC: 10796581.
DOI: 10.1007/s12325-023-02652-5.
Gliflozins: From Antidiabetic Drugs to Cornerstone in Heart Failure Therapy-A Boost to Their Utilization and Multidisciplinary Approach in the Management of Heart Failure.
Pistelli L, Parisi F, Correale M, Cocuzza F, Campanella F, De Ferrari T
J Clin Med. 2023; 12(1).
PMID: 36615178
PMC: 9820867.
DOI: 10.3390/jcm12010379.
Empagliflozin Preserves Skeletal Muscle Function in a HFpEF Rat Model.
Winzer E, Schauer A, Langner E, Augstein A, Goto K, Mannel A
Int J Mol Sci. 2022; 23(19).
PMID: 36232292
PMC: 9570453.
DOI: 10.3390/ijms231910989.
New insights and advances of sodium-glucose cotransporter 2 inhibitors in heart failure.
Li J, Zhou L, Gong H
Front Cardiovasc Med. 2022; 9:903902.
PMID: 36186974
PMC: 9520058.
DOI: 10.3389/fcvm.2022.903902.
Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure.
Jedrzejewska A, Braczko A, Kawecka A, Hellmann M, Siondalski P, Slominska E
Int J Mol Sci. 2022; 23(17).
PMID: 36077285
PMC: 9456495.
DOI: 10.3390/ijms23179886.
Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role?.
Elrakaybi A, Laubner K, Zhou Q, Hug M, Seufert J
Mol Metab. 2022; 64:101549.
PMID: 35863639
PMC: 9352970.
DOI: 10.1016/j.molmet.2022.101549.
Mitochondria-Mediated Cardiovascular Benefits of Sodium-Glucose Co-Transporter 2 Inhibitors.
Dabravolski S, Zhuravlev A, Kartuesov A, Borisov E, Sukhorukov V, Orekhov A
Int J Mol Sci. 2022; 23(10).
PMID: 35628174
PMC: 9140946.
DOI: 10.3390/ijms23105371.
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.
Abudureyimu M, Luo X, Wang X, Sowers J, Wang W, Ge J
J Mol Cell Biol. 2022; 14(5).
PMID: 35511596
PMC: 9465638.
DOI: 10.1093/jmcb/mjac028.
SGLT2 Inhibitors and Ketone Metabolism in Heart Failure.
Saucedo-Orozco H, Voorrips S, Yurista S, de Boer R, Westenbrink B
J Lipid Atheroscler. 2022; 11(1):1-19.
PMID: 35118019
PMC: 8792821.
DOI: 10.12997/jla.2022.11.1.1.
The promise and problems of metabolic-based therapies for heart failure.
Perez D
Interv Cardiol (Lond). 2021; 13(6):415-424.
PMID: 34970333
PMC: 8715677.
SGLT2 Inhibitors and Their Mode of Action in Heart Failure-Has the Mystery Been Unravelled?.
Pabel S, Hamdani N, Luedde M, Sossalla S
Curr Heart Fail Rep. 2021; 18(5):315-328.
PMID: 34523061
PMC: 8484236.
DOI: 10.1007/s11897-021-00529-8.
Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial.
Sorice G, Cinti F, Leccisotti L, DAmario D, Lorusso M, Guzzardi M
Diabetes Ther. 2021; 12(7):2101-2113.
PMID: 34037951
PMC: 8266960.
DOI: 10.1007/s13300-021-01083-1.
Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure.
Hundertmark M, Agbaje O, Coleman R, George J, Grempler R, Holman R
ESC Heart Fail. 2021; 8(4):2580-2590.
PMID: 33960149
PMC: 8318430.
DOI: 10.1002/ehf2.13406.
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial.
Butt J, Nicolau J, Verma S, Docherty K, Petrie M, Inzucchi S
Eur J Heart Fail. 2021; 23(4):601-613.
PMID: 33594755
PMC: 11497284.
DOI: 10.1002/ejhf.2124.
Pathophysiological Basis for Nutraceutical Supplementation in Heart Failure: A Comprehensive Review.
Mollace V, Rosano G, Anker S, Coats A, Seferovic P, Mollace R
Nutrients. 2021; 13(1).
PMID: 33477388
PMC: 7829856.
DOI: 10.3390/nu13010257.
